Table 2.
Methodological quality assessment of included studies judged using TESTEX scale
| Study quality | Study reporting | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Study | Item 1 | Item 2 | Item 3 | Item 4 | Item 5 | Item 6 | Item 7 | Item 8 | Item 9 | Item 10 | Item 11 | Item 12 | Overall | Judgement |
| Alves et al. [25] | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 6 | Fair |
| Bittman et al. [37] | 1 | 1 | 0 | 1 | 1 | 2 | 0 | 1 | 1 | 1 | 0 | 1 | 10 | Good |
| Joensen et al. [38] | 1 | 0 | 0 | 1 | 1 | 2 | 0 | 1 | 1 | 0 | 0 | 1 | 8 | Fair |
| Kato et al. [39] | 1 | 0 | 0 | 1 | 1 | 3 | 0 | 1 | 1 | 0 | 0 | 1 | 9 | Good |
| Kim et al. [40] | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 7 | Fair |
| Malmo et al. [41] | 1 | 0 | 0 | 1 | 1 | 3 | 0 | 1 | 1 | 0 | 0 | 1 | 9 | Good |
| Nourmohammadi et al. [42] | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 6 | Fair |
| Osbak et al. [43] | 1 | 1 | 1 | 1 | 1 | 2 | 0 | 1 | 1 | 0 | 0 | 1 | 10 | Good |
| Risom et al. [44] | 1 | 1 | 1 | 1 | 0 | 2 | 2 | 1 | 1 | 0 | 0 | 1 | 11 | Good |
| Borland et al. [45] | 1 | 1 | 1 | 1 | 1 | 3 | 2 | 1 | 1 | NA | 0 | 1 | 13 | Excellent |
| Reed et al. [26] | 1 | 1 | 1 | 1 | 1 | 0 | 2 | 1 | 1 | NA | 0 | 1 | 10 | Good |
| Skielboe et al. [46] | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 1 | NA | 0 | 1 | 12 | Excellent |
Item 1, eligibility criteria specified; Item 2, randomisation specified; Item 3, allocation concealment; Item 4, group similar at baseline; Item 5, blinding of assessor; Item 6, outcome measures assessed in 85% of patients; Item 7, intention-to-treat analysis; Item 8, between-group statistical comparisons reported; Item 9, point measures and measures of variability for all reported outcome measures; Item 10, activity monitoring in control groups; Item 11, relative exercise intensity remained constant; Item 12, exercise volume and energy expenditure; NA, non-applicable item due to study design